ESMO 2022 Conference Coverage


 

ESMO 2022 on 4.5-Year Follow-Up From KEYNOTE-240: Pembrolizumab vs. Placebo as 2L Treatment for Sorafenib-Treated aHCC

122 views
September 16, 2022
Comments 0
Login to view comments. Click here to Login